Molecular residual disease: Charting a new path for treating resectable solid tumors.
Molecular residual disease (MRD), detected via circulating tumor DNA (ctDNA) after curative-intent surgery, identifies resectable solid tumor patients at high recurrence risk, thereby enabling enriched trials with larger effect sizes and smaller samples. Yet enrichment narrows the eligible population and thus challenges conventional randomized designs.
Molecular residual disease (MRD), detected via circulating tumor DNA (ctDNA) after curative-intent surgery, identifies resectable solid tumor patients at high recurrence risk, thereby enabling enriched trials with larger effect sizes and smaller samples. Yet enrichment narrows the eligible population and thus challenges conventional randomized designs.
What the study was
- Study design
- Randomized Controlled Trial (inferred)
- Category
- Early Detection
- Maturity
- Potentially Practice-Changing
- Journal
- Cancer Cell
Why it surfaced
Matched watchlist topic 'Early cancer detection (liquid biopsy, ctDNA, cfDNA)'. Study design: Randomized Controlled Trial (inferred). Score: 9/10 (N:3, R:2, D:2, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.